EPINEPHrine IV Bags Recalled Due to Sterility Assurance Failure
Central Admixture Pharmacy Services, Inc. is recalling EPINEPHrine 8mg/250ml IV bags due to lack of sterility assurance and insufficient validation data for decontamination cycles. The recall affects 4,570 units distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving potential sterility issues with injectable medication. No illnesses or injuries have been reported in the source material, but the hazard presents significant risk due to the nature of sterile injectable pharmaceuticals and the lack of proper sterilization validation data.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling EPINEPHrine 8mg/250ml IV bags (32 mcg/mL in dextrose 5%). The manufacturer, located in Phoenix, Arizona, is withdrawing approximately 4,570 units that were distributed nationwide.
The recall was initiated due to lack of assurance of sterility. The manufacturer lacks adequate validation data for decontamination cycles, which are essential to ensure the product's sterility.
Affected lots include multiple batch numbers with expiration dates ranging from July 16, 2023 through September 7, 2023 (NDC: 72196-7019-1).
Healthcare providers who have received these IV bags should not use them and should remove them from inventory. Healthcare providers or patients who believe they have been exposed to this product should consult their healthcare provider. Adverse events should be reported to the FDA's MedWatch program.
The recalled product
- Product
- EPINEPHrine 8mg/250ml added to dextrose 5%, 32 mcg/mL, IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-7019-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable medication
- Affected units
- 4,570
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 36-240224
- Exp. 7/16/2023
- 36-242322
- EXP. 7/24/2023
- 36-242445
- Exp. 7/25/2023
- 36-243305
- Exp. 7/27/2023
- 36-243813
- Exp. 7/31/2023
- 36-246166
- 36-246167
- Exp. 8/3/2023
- 36-247670
- Exp. 8/9/2023
- 36-248992
- Exp.8/16/2023
- 36-249468
- Exp. 8/17/2023
- 36-249590
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 95 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 95 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22